1. Home
  2. SCYX vs GNS Comparison

SCYX vs GNS Comparison

Compare SCYX & GNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.26

Market Cap

60.4M

Sector

Health Care

ML Signal

HOLD

Logo Genius Group Limited

GNS

Genius Group Limited

HOLD

Current Price

$0.23

Market Cap

54.7M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
GNS
Founded
1999
2002
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
60.4M
54.7M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
SCYX
GNS
Price
$4.26
$0.23
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
329.4K
13.8M
Earning Date
05-06-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
61.36
N/A
EPS
N/A
N/A
Revenue
$257,000.00
N/A
Revenue This Year
N/A
$156.26
Revenue Next Year
$608.78
$35.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.21
52 Week High
$5.62
$1.92

Technical Indicators

Market Signals
Indicator
SCYX
GNS
Relative Strength Index (RSI) 72.96 40.24
Support Level $0.67 $0.21
Resistance Level $5.62 $0.48
Average True Range (ATR) 0.27 0.03
MACD 0.26 0.00
Stochastic Oscillator 73.19 11.61

Price Performance

Historical Comparison
SCYX
GNS

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About GNS Genius Group Limited

Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.

Share on Social Networks: